
07/24/2025
We welcome a significant advancement for the global Lipedema community: Germany’s Federal Joint Committee (G‑BA) has approved liposuction for inclusion in its standard insurance benefits. The G-BA has proposed to now cover patients at all stages when specific criteria have been met - not just Stage III, as in the past. Read the press release here: https://www.g-ba.de/presse/pressemitteilungen-meldungen/1274/?fbclid=IwZXh0bgNhZW0CMTAAYnJpZBExdTRWdlJ2V2pocVNmY1I1NwEeQMevc8hLcDnnqgN4H74h_NRzo4Jpk6UfN80y2MJUpicUpP_VH9lZgus4aNo_aem_OZB3JcPS_RdGtBOIHG5jLw
This decision was driven by findings from the LIPLEG study (https://pubmed.ncbi.nlm.nih.gov/34717741/), the first randomized, controlled, and blinded multi-center trial of its kind. Results of this trial, still to be published, demonstrated that liposuction has a benefit for treating Lipedema in the legs and/or arms, regardless of the stage. While procedural steps remain, this is a critical step forward.
We commend the investigators, whose work helped inform this outcome, and are hopeful this progress will support evidence-based improvements in Lipedema care worldwide.